Washington has turned a dispute over medicine prices into a formal trade investigation, placing Germany’s healthcare cost-cutting plans under US scrutiny and opening another front in transatlantic economic tensions.
The United States has opened a formal trade investigation into Germany’s proposed drug-pricing reforms, raising the prospect of new tariff action against German imports and widening a dispute between Washington and Europe over the cost of pharmaceutical innovation.
The Office of the US Trade Representative said it had launched an investigation under Section 301 of the Trade Act of 1974 into what it described as Germany’s “persistent underpayment” for innovative pharmaceutical products. The inquiry will examine whether German pricing practices are unreasonable or discriminatory, and whether they burden or restrict US commerce.
The move turns a healthcare funding dispute into a trade-policy matter. Germany has been seeking to reduce pressure on its public health system, including through measures affecting pharmaceutical spending. Washington’s response signals that drug-pricing decisions by European governments may now be treated not only as domestic health policy, but also as potential barriers to US commercial interests.
The investigation follows months of discussions between Washington and Berlin, according to the US trade authority. It will include a public comment process beginning on 25 June and a public hearing in September. If the investigation concludes that Germany’s practices are unfair under US trade law, Washington could seek remedial action, including tariffs.
The case is politically sensitive because Germany is both the EU’s largest economy and one of the most important pharmaceutical markets in Europe. It is also a central trading partner for the United States. Any US tariff response would therefore risk drawing the European Union into another trade dispute with Washington at a time when transatlantic economic relations are already affected by arguments over tariffs, industrial policy, energy, technology and strategic supply chains.
Germany’s proposed reforms are part of a broader effort to control healthcare expenditure. Berlin has been looking for savings from a system under pressure from demographic change, higher treatment costs and budget constraints. The German Health Ministry has been working on a wider healthcare reform agenda intended to address funding pressure in the statutory insurance system. For pharmaceutical companies, however, lower prices and larger discounts can reduce expected returns from new medicines and affect investment decisions.
That is the point on which Washington has focused. The US position is that American pharmaceutical companies bear a large share of the cost of research and development, while some foreign governments use price controls to pay less for the same products. US officials argue that this places an unfair burden on American companies and consumers.
Germany and other European countries are likely to view the issue differently. Their systems are based on public or statutory health insurance, negotiated prices and efforts to maintain access to treatment while controlling public expenditure. From that perspective, drug pricing is part of domestic health policy rather than a trade concession to foreign producers.
The dispute therefore goes beyond Germany. If the United States succeeds in using Section 301 to pressure a European government over medicine prices, other EU countries could face similar scrutiny. France, the Netherlands and other member states also use mechanisms to negotiate or regulate prices for medicines reimbursed by public systems.
For Brussels, the case could become a test of how the EU responds when Washington targets an individual member state over a policy area closely linked to national competence. Health policy remains primarily a national responsibility within the EU, but common commercial policy is handled at EU level. That creates an institutional complication: Germany may be the immediate target, but any tariff response would have broader consequences for EU-US trade relations.
The timing also matters. The United States has increasingly used trade instruments to pursue wider economic and strategic objectives. Section 301 gives Washington a legal route to investigate practices it considers unfair and to impose countermeasures if consultations fail. It has previously been used in disputes involving China, digital services taxes and other trade practices.
For the pharmaceutical industry, the German case may strengthen pressure on European governments to soften cost-cutting measures. Several companies have warned that aggressive pricing reforms could affect investment, product launches and research decisions. Governments, however, face their own political constraints: higher spending on medicines must be weighed against public budgets and wider healthcare priorities.
The immediate question is whether Germany can reach a settlement with Washington before the investigation reaches a tariff stage. Berlin may adjust parts of its reform package, particularly if industry pressure and US trade action create wider economic risk. But any visible concession could be politically difficult, as it would suggest that domestic healthcare policy is being shaped by foreign trade pressure.
For the EU, the case is another example of how trade disputes are moving into sectors previously treated mainly as domestic regulation. Drug pricing, public procurement, technology rules, digital markets and climate policy are increasingly exposed to trade retaliation. That trend narrows the space between internal policy and external economic pressure.
The German investigation is therefore not only about the price of medicines. It is about whether the United States can use trade law to challenge European healthcare systems, and whether EU governments can continue to regulate pharmaceutical costs without risking retaliatory action.
